Similar articles

• Preclinical predictors of clinical safety: opportunities for improvement.

  Sistare FD, DeGeorge JJ. Sistare FD, et al. Clin Pharmacol Ther. 2007 Aug;82(2):210-4. doi: 10.1038/sj.clpt.6100243. Epub 2007 May 16. Clin Pharmacol Ther. 2007. PMID: 17507920 Review.
• Short patent lives jeopardize drug and patient safety.

  Hondeghem LM, De Clerck F, Camm J. Hondeghem LM, et al. J Cardiovasc Pharmacol. 2007 Oct;50(4):353-7. doi: 10.1097/FJC.0b013e3181514032. J Cardiovasc Pharmacol. 2007. PMID: 18049301
• Promoting, improving and accelerating the drug development and approval processes.

  Graul AI. Graul AI. Drug News Perspect. 2007 Jan-Feb;20(1):45-55. Drug News Perspect. 2007. PMID: 17332899
• The marketplace can't give us the drug safety data we need.

  Avorn J. Avorn J. MedGenMed. 2007 Feb 9;9(1):29. MedGenMed. 2007. PMID: 17435636 Free PMC article. No abstract available.
• Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.

  [No authors listed] [No authors listed] J Clin Psychiatry. 1998;59 Suppl 12:10-6. J Clin Psychiatry. 1998. PMID: 9766614 Review.